Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback